medRxiv Oncology· Fennell, D. A., Dzialo, J., Zhang, M., Bzura, A., Poile, C., Baitei, E. Y., Dungey, M., Branson, A., King, A., Barber, S., Antoniou, M., Maarawi, F., Jama, M., Darlison, L., Scotland, M., Belcher, C., Bajaj, A., Morgan, B., Brookes, C., Faulkner, D., Rogel, J., Wells -Jordan, P., Richards, C. J., Luo, J.-L., Darlington, E., Carter, L., Little, M., Greystoke, A., Thomas, A., Luckett, M., Abdullah, M., Hahne, J. C., Zhou, Z., Yang, H., Dulloo, S., Haldar, K., Barer, M., Griffiths, G., Ewings, S., Hill, K., Tulchinsky, E., Nusrat, N. A., Kuse, N. C., Monkman, J., Tubelleza, R., Kilgallon, A., Kul ·· 7 天前精选评分56
MIST3 二期试验显示 AXL 和 PD1 联合抑制在间皮瘤中疾病控制率达 46.2%
Tumour extrinsic neutrophil regulation in mesothelioma correlates with responsiveness to AXL and PD1 inhibition in MIST3, a phase IIA clinical trial
导读
MIST3（NCT03654833）二期试验评估 bemcentinib（AXL 抑制剂）和 pembrolizumab（PD1 抑制剂）联合治疗 ICB 初治复发间皮瘤患者，达到主要终点，12 周疾病控制率为 46.2%（90% CI 29.2–63.8%）。
来源：medRxiv Oncology · medrxiv.org